Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →What is the biggest risk to Eli Lilly stock? A large share of the company’s sales growth now depends on Mounjaro and Zepbound. Together, they generated about 64.7% of Lilly’s Q2 2026 revenue, a calculation from the company’s reported figures. That concentration makes the growth story unusually sensitive to changes in demand, pricing, access, competition, supply, safety, regulation and patent protection.
Why Mounjaro and Zepbound concentration matters
Lilly reported $22.974 billion in Q2 2026 revenue, up 48% from a year earlier. Mounjaro brought in $9.943 billion, up 91%, and Zepbound brought in $4.928 billion, up 46%. Their combined $14.871 billion represented approximately 64.7% of the quarter’s revenue; that percentage is calculated from Lilly’s reported figures, not a company-published statistic. (Eli Lilly and Company, Q2 2026 results, August 5, 2026.)
The products are both based on tirzepatide. That means two fast-growing brand names do not necessarily represent two independent sources of growth: developments affecting the shared medicine, its supply, or its market could matter to both. A slowdown or setback affecting either product would also carry more weight when the products make up such a large portion of sales.
This is a risk of exposure, not a prediction that demand will weaken or that an adverse event will occur. Lilly’s 2025 Form 10-K, filed in February 2026, identifies dependence on a relatively small number of products or product classes as a risk that could materially affect results and contribute to sudden stock-price volatility.
#1 Best Overall
Volume is growing, but realized prices are falling
Sales growth is not the same as rising prices. In Q2 2026, Lilly’s global revenue increased 48%, reflecting 60% volume growth partly offset by a 13% decline in realized prices. The volume gains show substantial demand growth; the price decline is a separate pressure that investors should track alongside sales.
The mix differed by geography. Lilly reported that international growth included a substantial fall in realized prices, which it attributed primarily to Mounjaro’s addition to China’s National Reimbursement Drug List.
| Q2 2026 geography | Revenue growth year over year | Volume change | Realized-price change | Company-reported context |
|---|---|---|---|---|
| United States | 33% | Up 37% | Down 3% | Reported by Eli Lilly in its Q2 2026 results. |
| Outside the United States | 80% | Up 113% | Down 36% | Lilly said the realized-price decline was primarily due to Mounjaro’s addition to China’s National Reimbursement Drug List. |
These figures are company-reported Q2 2026 results, not a forecast of future prices or growth. Reimbursement and payer access can affect how much revenue Lilly realizes even when demand or prescription volume rises.
How concentration can amplify other risks
Lilly’s 2025 Form 10-K names several kinds of developments that could affect a concentrated product mix. They are risks disclosed by the company, not evidence that any particular problem is occurring.
- Competition: Other medicines or competing treatments could affect demand, market share or the terms on which products are reimbursed.
- Pricing and access: Changes in realized prices, coverage or reimbursement can limit revenue even if sales volume grows.
- Safety and regulation: New safety information or regulatory action could affect use, approvals or commercial prospects.
- Supply: Manufacturing constraints or execution problems could prevent Lilly from meeting demand.
- Patents: Changes affecting patent protection could alter the period in which products face limited competition.
Because Mounjaro and Zepbound account for such a substantial share of current sales, changes in any of these areas could have an outsized effect on the business and its growth expectations. Whether they affect the share price, and by how much, cannot be determined from the quarterly figures alone.
What Lilly’s guidance and pipeline do—and do not—show
On August 5, 2026, Lilly raised its full-year revenue guidance to $85 billion–$87 billion. It reported 2026 earnings-per-share guidance of $35.50–$36.50. The company also said it raised its underlying non-GAAP EPS guidance by $2.78 at the midpoint, more than offset by $3.03 per share of acquired in-process research and development charges from Q2 business-development activity. Reported EPS guidance and underlying non-GAAP guidance are different measures and should not be treated as interchangeable.
The higher revenue outlook is evidence of Lilly’s confidence in its near-term business, not a guarantee that it will meet the range. Similarly, pipeline progress may broaden the business over time, but submission plans and clinical results are not approved products or assured revenue.
- Lilly reported sales of Foundayo and an orforglipron submission for type 2 diabetes in the United States.
- The company said retatrutide’s clinical data package supported planned global registration submissions for obesity, obstructive sleep apnea and knee osteoarthritis pain, with a U.S. BLA submission planned for Q1 2027.
- Lilly described a further $4.5 billion commitment to Indiana manufacturing sites, acquisitions, and clinical or regulatory milestones. The announcement is an investment commitment, not proof that additional capacity is already operating or that any development will succeed.
Lilly chair and CEO David A. Ricks said in the August 5, 2026 results release: “Lilly’s momentum continues, as we delivered 48% revenue growth and raised our full-year guidance,”. That is company commentary, not an independent assessment of the stock or a guarantee of future performance.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minuteDoes this mean Eli Lilly stock is overvalued?
These operating figures and risk disclosures do not establish whether Lilly shares are cheap or expensive. A valuation conclusion would require current share-price data and a stated comparison, such as a dated earnings multiple, alongside assumptions about future earnings growth. Without that information, the supportable conclusion is about business concentration and execution sensitivity—not the stock’s valuation.
For investors assessing the risk, the useful questions are whether volume can keep growing, how it compares with realized-price changes, whether reimbursement and access remain supportive, whether supply keeps pace, and how much future growth comes from products beyond Mounjaro and Zepbound. Lilly’s guidance and pipeline provide context for those questions, but they do not remove the uncertainty.
This is general business-risk information, not individualized investment advice.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
